← FDA DRUG APPROVALS

FDA ANDA · ANDA089243

LANIAZID

Sponsor: LANNETT

APPLICATION
ANDA089243
TYPE
ANDA
ORIGINAL APPROVAL
1986-02-03
LATEST ACTION
2025-02-05
ROUTE
ORAL
DOSAGE FORM
SYRUP
MARKETING STATUS
Discontinued

Products

LANIAZIDDiscontinued
ISONIAZID 50MG/5ML · SYRUP · ORAL

Approval history

2025-02-05Labeling · Supplement 12 · standardAP
1990-01-09Labeling · Supplement 4AP
1987-09-09Manufacturing (CMC) · Supplement 2AP
1987-09-09Manufacturing (CMC) · Supplement 3AP
1987-09-09Manufacturing (CMC) · Supplement 1AP
1986-02-03OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →